Charline Caumont

Pessac-sur-dordogne, 33600, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Fluorescent In Situ Hybridization Testing Allows the Diagnosis of NRG1 Gene Fusions in Lung and Pancreas Cancers with No Other Identified Oncogenic Driver.

Fluorescent In Situ Hybridization Testing Allows the Diagnosis of NRG1 Gene Fusions in Lung and Pancreas Cancers with No Other Identified Oncogenic Driver.

Journal: Cancers

Published: June 04, 2025

Recurrent primary cutaneous marginal zone lymphoma: a comparative study of initial tumours, recurrences, and outcomes in 61 patients.

Recurrent primary cutaneous marginal zone lymphoma: a comparative study of initial tumours, recurrences, and outcomes in 61 patients.

Journal: Histopathology

Published: August 10, 2024

COPD patients with non-small cell lung cancer respond better to anti-PD-(L)1 immune checkpoint inhibitors.

COPD patients with non-small cell lung cancer respond better to anti-PD-(L)1 immune checkpoint inhibitors.

Journal: Scientific reports

Published: July 17, 2024

Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe.

Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe.

Journal: ESMO open

Published: April 13, 2023

Giant syringocystadenocarcinoma papilliferum with conjunctival recurrence: Possible Schimmelpenning syndrome with postzygotic G13R HRAS and K601N BRAF signature.

Giant syringocystadenocarcinoma papilliferum with conjunctival recurrence: Possible Schimmelpenning syndrome with postzygotic G13R HRAS and K601N BRAF signature.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: March 20, 2023

Performances of the Idylla GeneFusion Assay: contribution to a rapid diagnosis of targetable gene fusions in tumour samples.

Performances of the Idylla GeneFusion Assay: contribution to a rapid diagnosis of targetable gene fusions in tumour samples.

Journal: Journal of clinical pathology

Published: January 24, 2023

Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC.

Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC.

Journal: JTO clinical and research reports

Published: October 18, 2022

Assessment of Liquid Biopsy in Primary Cutaneous Diffuse Large B-Cell Lymphoma-Leg Type.

Assessment of Liquid Biopsy in Primary Cutaneous Diffuse Large B-Cell Lymphoma-Leg Type.

Journal: The Journal of investigative dermatology

Published: October 06, 2022

An EZH2 blocker sensitizes histone mutated diffuse midline glioma to cholesterol metabolism inhibitors through an off-target effect.

An EZH2 blocker sensitizes histone mutated diffuse midline glioma to cholesterol metabolism inhibitors through an off-target effect.

Journal: Neuro-oncology advances

Published: March 18, 2022

Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer.

Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 14, 2022

Molecular profile of non-small cell lung cancer in reunion Island.

Molecular profile of non-small cell lung cancer in reunion Island.

Journal: Respiratory medicine and research

Published: October 15, 2021

MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories.

MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories.

Journal: Human pathology

Published: March 21, 2021

Showing 1-12 of 24

Last Updated: 09/26/2026